It was a decade that began with the electrifying results of a clinical trial for a revolutionary new cancer therapy and ended with a Nobel Prize in Medicine for very different cancer-related research. In between those dramatic bookends, the 2010s were packed with progress, with discoveries leading to the FDAs 2017 approval of the first CAR T-cell therapy. Additional approvals would follow.
The 2010s started with clinical trial results centered on the use of checkpoint inhibitors, drugs that unleash a powerful immune system attack on cancer cells. The results founded on decades of research by scientists like Dana-Farbers Gordon Freeman, PhD helped usher in a new era of cancer immunotherapy.
Checkpoint blockersare transformational, Laurie H. Glimcher, MD, president and CEO of Dana-Farber and a prominent immunologist, said back in 2017, but they are only the tip of a proverbial immunotherapy iceberg.
On the other side of the last 10 years in cancer research was the Nobel Prize in Medicine, shared by Dana-Farbers William G. Kaelin, Jr., MD, for discoveries into the mechanism that enables cells to sense and adapt to changes in oxygen abundance research that has already led to exciting new treatments for cardiovascular disease and cancer.
As cancer research pioneer and Dana-Farber founder Sidney Farber, MD, said back in 1965, I have never accepted the incurability of cancer. And I have remained hopeful, not because of wishful thinking thats not progress but because of the factual evidence of progress. There is no such thing as a hopeless case.
Aside from these prominent discoveries, what were the most significant advances in cancer research and treatment? Heres what scientists and clinicians from around Dana-Farber said.
William Hahn, MD, PhD, Chief Research Strategy Officer
The sequencing of human cancer genomes over the past decade has demystified the genetics of cancer. We now have a blueprint of cancer genes in every type of cancer and information about the frequency and type of mutations that occur. This has revealed new genes and pathways important for cancer development and in some cases has already led to new approved cancer therapies.
In addition, geneticallysequencing tumor tissue samples guides the therapeutic agents selected for asubset of cancer patients. This tailored approach, termed precision medicine,selects patients most likely to respond and spares those that are unlikely torespond from untoward side effects. Recent discoveries that its possible tosequence DNA in the blood to detect cancers provide hope that this approach canbe used to identify cancers earlier and follow the response to therapy.
Through the study of rare cancers, we have identified mutations in genes that regulate the epigenome, the cells machinery for activating and deactivating genes. These studies have revealed that these same pathways are dysregulated in many common cancers and play key roles in cancer pathogenesis and resistance to therapy.
Sapna Syngal, MD, MPH, Director of Research, Center for Cancer Genetics and Prevention
The realization that upto 10% of many solid tumors have an inherited genetic basis provides us with agreat opportunity for precision prevention and early interception.
Scott Armstrong, MD, PhD, President, Dana-Farber/Boston Childrens Cancer and Blood Disorders Center
Were now able to identify several premalignant states that significantly increase peoples risk of developing certain hematologic cancers. Individuals with clonal hematopoiesis of indeterminate potential (CHIP), for example, have certain genetic mutations in their blood-forming stem cells that are associated with leukemia.
People with CHIP dont have symptoms of disease, but their risk of developing a blood cancer such as leukemia is 10 times higher than average and their risk of cardiovascular disease is elevated as well. Being able to identify high-risk individuals means we can begin to think about early-intervention strategies to prevent these cancers from developing an active area of research.
Ursula Matulonis, MD, Chief, Division of Gynecologic Oncology
The introduction of drugs known as PARP inhibitors has had a major impact on the treatment of ovarian cancer, and now they are showing effectiveness against other cancers including breast and pancreatic. PARP inhibitors work by blocking one of the key routes by which cells repair damaged DNA and are especially effective in cancers with existing DNA-repair deficiencies such as those harboring BRCA mutations.
Also, better understanding of the genomics of gynecologic cancers the set of genetic mutations within the cancer cells is transforming the way we approach treatment and prevention. Its now widely recognized that women with ovarian cancer, regardless of age, histology type, or the stage at which their cancer is diagnosed, should undergo genetic testing. A percentage of them will have a predisposing mutation in one of the BRCA genes. Women with newly diagnosed endometrial cancer should have their cancer tested for mismatch repair deficiencies, which interfere with the proper copying of DNA during cell division.
The presence of these genetic features not only influences the treatment patients receive, but, because they can be inherited, often enable us to identify family members who are also at risk and can benefit from more intensive monitoring or preventive treatment.
Richard Stone, MD, Program Director in Adult Leukemia
Morethan 10 drugs have been approved for acute leukemia in the past three years,whereas there had been very few new agents in the previous 25 years.
DNA sequencing of patients leukemia cells to identify mutations is being used to help guide treatment decisions.
Eric Winer, MD, Senior Vice President for Medical Affairs and Faculty Development; Chief, Division of Breast Oncology
In the treatment of breast cancer, we now know for a certainty that one size does not fit all. This allows us to personalize therapy to a much greater extent than ever before. In some patients, this means we can treat them with less-intensive therapy and still obtain excellent results. Others may require more extensive therapy or benefit from a different therapeutic approach. For all patients, this means better, more effective care, fewer side effects, and, for many, a longer life.
Kimberly Stegmaier, MD, Vice Chair of Pediatric Oncology Research
There have been multiple approvals of new targeted drugs in adult acute myeloid leukemia (AML) in the past two years, as well as TRK inhibitor approval for adult and pediatric patients with TRK fusion-positive cancers.
Bruce Johnson, MD, Chief Clinical Research Officer
Addingthe kinase inhibitor midostaurin to standard chemotherapy significantlyprolonged overall and event-free survival in patients with acute myeloidleukemia whose cancer cells have a FLT3 mutation.
Enzalutamide,an androgen receptor inhibitor, was associated with significantly longer progression-freeand overall survival than standard care in men with metastatic,hormone-sensitive prostate cancer receiving testosterone suppression.
Dana-Farberscientists reported on the feasibility, safety, and immunogenicity of apersonalized cancer vaccine that caused immune T cells to recognizecancer-related neoantigens on tumor cells. These results have promptedfurther development of a neoantigen vaccine approach.
Nadine Jackson McCleary, MD, MPH, Gastrointestinal Oncologist
Weve made strides in ensuring that evidence from cancer research studies actually makes its way into clinical practice. For too long, research findings often seemed to remain in academia without being translated to clinical medicine.
Professional and patient advocacy organizations have undertaken a variety of steps to not only implement these advances in the clinical setting but also to make sure theyre sustainable. For example, organizations such as the American Society of Clinical Oncology (ASCO) and cooperative research groups regularly inform the broader public about research results and work at the state and federal level on behalf of patients. The development of implementation science is having a sizable impact on clinical practice.
Were also making progress in improving equity in cancer care delivery. Where equity issues have traditionally involved issues such as race, gender, and socioeconomic status, were broadening the focus to include considerations of gender identity, patient location (where patients receive treatment may affect their outcome), and treatment of the very youngest and oldest patients. These efforts will help ensure that advances in cancer medicine reach all populations.
Toni Choueiri, MD, Director of the Lank Center for Genitourinary Oncology
An important ongoing approach is liquid biopsies obtaining tumor-related DNA in the blood as a means of early cancer detection. Liquid biopsies also have the potential to detect minimal residual disease in the body following surgery to predict the risk of relapse.
Rameen Beroukhim, MD, PhD, Physician-Scientist in Neuro-Oncology
This decade is the first in which targeting collateral vulnerabilities in cancer cells has become an important strategy. Most efforts at treating cancer focus treatment on the genetic changes within cells that cause them to become cancer. But along the way, many genes that have nothing to do with cancer are also affected, and scientists have found that targeting these genes on which the cancer cells depend can be an effective way of attacking cancer. Immunotherapy, for example, detects cancer cells based on this collateral damage.
I predict that targeting collateral vulnerabilities will become increasingly important in future decades. Another recent strategy is based on the emerging technology of protein degradation, which removes cancer-related proteins from cells rather than simply binding to these proteins to inhibit their activity.
- Global Stem Cell Market Poised for Strong Growth as Global Regenerative Medicine Market Poised to Reach US$45 billion by 2025 - P&T Community - February 28th, 2020
- Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business Update - BioSpace - February 28th, 2020
- Creative Medical Technology Holdings Inc (OTCMKTS: CELZD) Gets the Extra D - MicroCap Daily - February 28th, 2020
- If medications fail, surgery option for treating infectious retinitis - Ophthalmology Times - February 28th, 2020
- BTK Inhibitors Offer Improved Response Over Chemotherapy in Mantle Cell Lymphoma - Curetoday.com - February 28th, 2020
- Aspire Regenerative Medical Director Featured on New Podcast - PR Web - February 28th, 2020
- Global Regenerative Medicine Market Briefing 2020, Trends, Applications, Types, Research, Forecast To 2025 - Bandera County Courier - February 28th, 2020
- New study identifies trigger that turns dormant cancer stem cells into active ones - Yahoo Finance - February 27th, 2020
- Editas Medicine Announces Fourth Quarter and Full Year 2019 Results and Update - Yahoo Finance - February 27th, 2020
- On the Road to 3-D Printed Organs - The Scientist - February 27th, 2020
- Researchers have found a probable cure for diabetes and we need to thank diabetic lab mice for it - International Business Times, Singapore Edition - February 27th, 2020
- Kiadis Pharma announces FDA clearance of clinical study by The Ohio State University in R/R AML with off-the-shelf NK cells from universal donors -... - February 27th, 2020
- Immune-Based Therapies Emerge in Mantle Cell Lymphoma - Curetoday.com - February 24th, 2020
- Texas A&M Researcher Named To National List Of Inspiring Black Scientists - Texas A&M University - February 24th, 2020
- Locking in and preserving your healthy stem cells has never been easier and more accessible as Acorn Biolabs partners with Coverdale Clinics. - Canada... - February 22nd, 2020
- Chinese Scientist Unite Together to Tackle With COVID-19 - Benzinga - February 22nd, 2020
- Army spouse dances her way through chemotherapy - We Are The Mighty - February 22nd, 2020
- The Winnipeg Foundation Innovation Fund supports cutting-edge research - UM Today - February 22nd, 2020
- Locking in and preserving your healthy stem cells has never been easier and more accessible as Acorn Biolabs partners with Coverdale Clinics. - Yahoo... - February 20th, 2020
- Missouri S&T researchers create organ tissue with bioactive glass, stem cells and 3D printer - The Rolla Daily News - February 20th, 2020
- Regenerative Medicine Market trends, leaders, segment analysis and forecast to 2030 described in a new market report - WhaTech Technology and Markets... - February 16th, 2020
- 5 Aesthetic Clinics To Know In The Klang Valley & Their Signature Treatments - Malaysia Tatler - February 14th, 2020
- Tech Ventures kicks off series dedicated to supporting female inventors and entrepreneurs at Johns Hopkins - The Hub at Johns Hopkins - February 14th, 2020
- BrainStorm Cell Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Provide a Corporate Update - GlobeNewswire - February 11th, 2020
- CD229 CAR T-cell therapy treated tumours had lasting response mice - Drug Target Review - February 11th, 2020
- BrainStorm Cell Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Provide a Corporate Update - BioSpace - February 11th, 2020
- Early Findings Show Promise of CAR NK-Cell Therapy in Leukemia, Lymphoma - Cancer Network - February 9th, 2020
- Physical forces at the interface with biology and chemistry - PLoS Blogs - February 9th, 2020
- Scientists create 'Chemical gardens' that can be used as bone substitute materials - University of Birmingham - February 7th, 2020
- Lab-grown heart cells implanted into human patient for the first time - New Atlas - January 29th, 2020
- Engineer the future of human health with a PhD in biomedical engineering - Study International News - January 29th, 2020
- GIOSTAR Announces Medical Breakthrough in Biotechnology and Lifesciences To Manufacture Abundant, Safe Red Blood Cells From Stem Cells - Benzinga - January 29th, 2020
- Study suggests Parkinson's present from birth and may be preventable - New Atlas - January 29th, 2020
- Celavie Biosciences Presented Five-Year Follow-Up Data in Parkinsonian Patients at the World Stem Cell Summit - Yahoo Finance - January 22nd, 2020
- The Brave New World of Organoids - North Forty News - January 22nd, 2020
- The Tiny Brain Cells That Connect Our Mental and Physical Health - WIRED - January 22nd, 2020
- Organicell Regenerative Medicine Inc. Provides Update On Operations and Financial Reporting Status - GlobeNewswire - January 22nd, 2020
- Novel mutations in stem cells of young donors can be passed to recipients - BioNews - January 21st, 2020
- Gains in Stem Cell Transplant Mortality Over Last 25 Years - MedPage Today - January 21st, 2020
- Biomedical Applications of Zeolitic Nanoparticles, with an Emphasis on | IJN - Dove Medical Press - January 21st, 2020
- Cell therapy trialed in mice offers diabetes treatment hope - SelectScience - January 21st, 2020
- Scientists Image Heart RNA Structure for the First Time - Diagnostic and Interventional Cardiology - January 21st, 2020
- CAR T-Cell Therapy and Beyond: Off-the-Shelf Therapies Among Innovations at ASH 2019 - AJMC.com Managed Markets Network - January 21st, 2020
- Stem Cell Assay Market to Expand at a Healthy CAGR of XX% Between and 2017 2025 Dagoretti News - Dagoretti News - January 21st, 2020
- Introducing Generate Life Sciences - A First-Of-Its-Kind Company Focused On Helping Grow And Protect Healthy Families - Yahoo Finance - January 19th, 2020
- Editas Medicine and Sandhill Therapeutics, Inc. Announce Collaboration to Develop Engineered Cell Medicines to Treat Cancer - Yahoo Finance - January 19th, 2020
- Regenerative Medicine Market 2026: Product Approvals and Growing Pipeline of Regenerative Medicine P - PharmiWeb.com - January 18th, 2020
- Mutations in donors' stem cells may cause problems for cancer patients - Washington University School of Medicine in St. Louis - January 18th, 2020
- Global Cell Expansion Market by Type, Share Analysis, Top Players Eyeing to Penetrate Into Emerging Nations with Untapped Opportunities 2024 ... - January 18th, 2020
- Introducing Generate Life Sciences - A First-Of-Its-Kind Company Focused On Helping Grow And Protect Healthy Families - PRNewswire - January 18th, 2020
- Stem Cell and Regenerative Medicine Action Awards to be Presented at World Stem Cell Summit on January 23 at the Hyatt Regency Miami - GlobeNewswire - January 12th, 2020
- SNACS: The FAANG Of The Roaring 20s - Yahoo Finance - January 12th, 2020
- 20 Technology Metatrends That Will Define the Next Decade - Singularity Hub - January 12th, 2020
- LANL Scientists And International Partners Create 3-D Image Of Heart RNA Structure For First Time - My Blog - Los Alamos Daily Post - January 12th, 2020
- MicroCures Awarded $1.5M SBIR Grant To Support Development of Novel Therapeutic Platform for Accelerated Tissue Repair - BioSpace - January 8th, 2020
- 2020 Exosome Technologies Market Top Companies Analysis Including Capricor Therapeutics Inc, Evox Therapeutics Ltd, ReNeuron Group Plc, Stem Cell... - January 8th, 2020
- Gene editing breakthroughs that cured genetic diseases in 2019 - The Star Online - January 5th, 2020
- BrainStorm Cell Therapeutics Wins 2020 'Buzz of BIO' Award for ALS Investigational Therapy - ALS News Today - January 3rd, 2020
- Cell and Advanced Therapies Supply Chain Management Industry Report, 2019-2030 - GlobeNewswire - January 3rd, 2020
- miRNAs: A Promising Target in the Chemoresistance of Bladder Cancer | OTT - Dove Medical Press - January 3rd, 2020
- China confirms third birth of gene-edited baby; scientists involved get prison terms - WRAL Tech Wire - January 3rd, 2020
- Gene Therapies Make it to Clinical Trials - Discover Magazine - December 31st, 2019
- What is HLH, and what role did it play in the death of a healthy 34-year-old ESPN reporter? - FirstCoastNews.com WTLV-WJXX - December 29th, 2019
- 2019: The year gene therapy came of age - INQUIRER.net - December 29th, 2019
- Stem Cells Market is Expected to Expand at an Impressive Rate by 2023 - News Cast Report - December 29th, 2019
- ESPN reporter diagnosed with pneumonia, HLH. What is HLH? - Crossroads Today - December 27th, 2019
- 2019: the year gene therapy came of age - Times of India - December 27th, 2019
- This Is How Human Head Transplants Could Be Achieved, According To A Neurosurgeon - IFLScience - December 25th, 2019
- Taiwan Healthcare+ Expo 2019: A 360 exposure to MedTech and Therapeutic world - BSA bureau - December 22nd, 2019
- Lawmakers Present Mother & Daughter With the Signed Bill They Inspired - River Journal Staff - December 22nd, 2019
- Sorrento Announces Dr. Robin Smith as New Member of the Board of Directors - GlobeNewswire - December 22nd, 2019
- Association Between Change in Circulating Progenitor Cells During Exercise Stress and Risk of Adverse Cardiovascular Events in Patients With Coronary... - December 20th, 2019
- Metabolic dysregulation: origins of neurodegenerative disease - Health Europa - December 20th, 2019
- Inside the US-Iran prisoner swap, and what comes next - Al-Monitor - December 20th, 2019
- Global Stem Cell Therapy Market to Surpass US$ 40.3 Billion by 2027 Coherent Market Insights - Business Wire - December 18th, 2019
- The 3D cell culture market is projected to reach USD 1,846 million by 2024 from USD 892 million in 2019, at a CAGR of 15.7% - PRNewswire - December 18th, 2019
- Orthopaedic Surgeon, Dr. Jeffrey Carlson, first in Central and Eastern Virginia to implant the M6-C Artificial Cervical Disc - BioSpace - December 18th, 2019
- Gene Therapy for Sickle-Cell Anemia Looks Promisingbut It's Riddled With Controversy - Singularity Hub - December 18th, 2019
- Orbiting Organoids: Research in Space to Unveil New Neurodegeneration Insight - Xconomy - December 18th, 2019
- Dr. Jack Zamora Partners with the Exclusive Haute Beauty Network - PR Web - December 18th, 2019